Edition:
United Kingdom

Spark Therapeutics Inc (ONCE.O)

ONCE.O on Nasdaq

52.55USD
9 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$52.55
Open
$51.65
Day's High
$53.18
Day's Low
$48.99
Volume
625,950
Avg. Vol
903,157
52-wk High
$91.75
52-wk Low
$41.06

Chart for

About

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a... (more)

Overall

Beta: --
Market Cap(Mil.): $3,132.52
Shares Outstanding(Mil.): 35.82
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Spark Therapeutics Reports Cash And Cash Equivalents And Marketable Securities Of $540.2 Mln As Of Dec. 31, 2017

* SPARK THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

12:57pm GMT

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

25 Jan 2018

UPDATE 1-Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

25 Jan 2018

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Jan 24 Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday.

24 Jan 2018

BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.

* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S.

24 Jan 2018

Spark's price for Luxturna blindness gene therapy too high: ICER

The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

12 Jan 2018

UPDATE 1-Spark's price for Luxturna blindness gene therapy too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

12 Jan 2018

CORRECTED-Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

Jan 12 The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

12 Jan 2018

BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH

12 Jan 2018

Spark to charge $850,000 per patient for blindness gene therapy

Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

03 Jan 2018

Earnings vs. Estimates